Updated recommendations advocate doing more to determine fracture risk and the need for preventive therapy
New GIOP Guidelines Available
The ACR published new recommendations for the management of glucocorticoid-induced osteoporosis (GIOP) in the November issue of Arthritis Care & Research. These guidelines have been endorsed by the American Society for Bone and Mineral Research. They apply to adult patients receiving oral glucocorticoid therapy.
Glucocorticoid-Induced Osteoporosis
Osteoporosis is a condition of weak bone caused by a loss of bone mass and a change in bone structure. Glucocorticoid-induced osteoporosis is a form of osteoporosis caused by taking glucocorticoid medications, such as prednisone (Deltasone, Orasone, etc.), prednisolone (Prelone), dexamethasone (Decadron, Hexadrol), and cortisone (Cortone Acetate). These medications are used to help control many rheumatic diseases, including RA, systemic lupus erythematosus, and polymyalgia rheumatica.